Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06874621 · ClinicalTrials.gov registry record · Phase 1
VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's Disease
A Phase 1 study of Alzheimer's Disease (AD), sponsored by Voyager Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
- 20
- Study locations
NCT06874621: Active Phase 1 study of Alzheimer's Disease (AD), sponsored by Voyager Therapeutics.
NCT06874621 is a Phase 1 study of Alzheimer's Disease (AD) that is active but no longer recruiting, run by Voyager Therapeutics. The registered enrollment target is 52 participants, below the 870-participant average among 3 other Alzheimer's Disease (AD) trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06874621, a Phase 1 study of Alzheimer's Disease (AD), is active but no longer recruiting, sponsored by Voyager Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is to be conducted in participants with early Alzheimer's Disease to test VY7523, a new drug being researched for treatment of Alzheimer's Disease. This study will look at how safe the drug is and how it works in the brain. It was first tested in normal, healthy participants who volunteered to participate. The study will look at three different dose levels, starting with the lowest dose first and moving to higher doses and more participants after safety has been reviewed by doctors and researchers. Some patients will receive drug while others will receive placebo. This will help to better compare how the drug works between participants receiving drug and placebo. The study will last up to 6 months for the lower dose groups and 12 months for the highest dose group.
Primary Outcome
Incidence of treatment-emergent adverse events (TEAEs) and clinically significant changes from baseline
Conditions Studied
Interventions
- DRUG Placebo Comparator
- DRUG VY7523
Study Locations (20)
Florida
- VYGR Site 840005 - Delray Beach
- VYGR Site 840021 - Fort Myers
- VYGR Site 840010 - Lady Lake
- VYGR Site 840015 - Miami
- VYGR Site 840014 - Miami
- VYGR Site 840024 - Miami
- VYGR Site 840006 - Orlando
- VYGR Site 840003 - Stuart
- VYGR Site 840004 - The Villages
- VYGR Site 840002 - Wellington
- VYGR Site 840020 - Winter Park
California
- VYGR Site 840018 - Los Angeles
- VYGR Site 840016 - Orange
- VYGR Site 840022 - San Francisco
Connecticut
- VYGR Site 840008 - Stamford
Georgia
- VYGR Site 840007 - Decatur
New Jersey
- VYGR Site 840012 - Toms River
North Carolina
- VYGR Site 840009 - Matthews
Pennsylvania
- VYGR Site 840011 - Plymouth Meeting
Ontario
- VYGR Site 124002 - Ottawa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2025-03-03 |
| Est. Completion | 2027-05 |
| Phase | Phase 1 |
What the registry record for NCT06874621 still lists
NCT06874621 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 870-participant average among 3 other Alzheimer's Disease (AD) trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Alzheimer's Disease (AD) appearing as the primary indexed condition, and to 2 interventions - of which Placebo Comparator is the first listed.
NCT06874621 names 20 study sites across 8 states, led by Florida, California, Connecticut.
Frequently Asked Questions
What is clinical trial NCT06874621 about?
NCT06874621 is a clinical study titled "VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's Disease". This study is to be conducted in participants with early Alzheimer's Disease to test VY7523, a new drug being researched for treatment of Alzheimer's Disease. This study will look at how safe the drug is and how it works in the brain. It was first tested in normal, healthy participants who volunteer...
What is the current status of trial NCT06874621?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2025-03-03. Estimated completion is 2027-05.
What conditions does trial NCT06874621 study?
This clinical trial studies the following conditions: Alzheimer's Disease (AD).
What interventions are being tested in trial NCT06874621?
The interventions under investigation include: Placebo Comparator (DRUG), VY7523 (DRUG).
Who is sponsoring clinical trial NCT06874621?
This trial is sponsored by Voyager Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06874621 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Georgia, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer's Disease (AD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Improving Executive Control in Cognitively Healthy Older Adults: the MUltitasking STrategy (MUST) Study
RECRUITING · NA
-
Development of Measures to Screen for Financial Hardship in Alzheimer's Disease and Dementia
RECRUITING
-
Effects of Transcranial Ultrasound Stimulation (TUS) on Neurological and Cognitive Outcomes in Neurodegenerative Diseases
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI